

Availability, price and affordability of cardiovascular medicines in low-income and middle-income countries using WHO/HAI data

BMC Cardiovascular Disorders

10, 25

DOI: [10.1186/1471-2261-10-25](https://doi.org/10.1186/1471-2261-10-25)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Understanding and Advancing the Health of Older Populations in sub-Saharan Africa: Policy Perspectives and Evidence Needs. <i>Public Health Reviews</i> , 2010, 32, 357-376.	1.3	55
2	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. <i>Lancet</i> , The, 2011, 378, 1231-1243.	6.3	803
3	Should There Be a Different Cardiovascular Prevention Polypill Strategy for Women and Men?. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 280-286.	0.8	0
4	Local production of medical technologies and its effect on access in low and middle income countries: a systematic review of the literature. <i>Southern Med Review</i> , 2011, 4, 51-61.	0.8	17
5	Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. <i>Bulletin of the World Health Organization</i> , 2011, 89, 412-421.	1.5	135
6	Global Variation in the Prevalence of Elevated Cholesterol in Outpatients With Established Vascular Disease or 3 Cardiovascular Risk Factors According to National Indices of Economic Development and Health System Performance. <i>Circulation</i> , 2012, 125, 1858-1869.	1.6	39
7	Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. <i>Globalization and Health</i> , 2012, 8, 22.	2.4	40
8	Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. <i>Epilepsia</i> , 2012, 53, 962-969.	2.6	81
9	Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all. <i>BMC Health Services Research</i> , 2013, 13, 285.	0.9	46
10	Noncommunicable Diseases. <i>New England Journal of Medicine</i> , 2013, 369, 1336-1343.	13.9	393
11	Scaling Up Chronic Disease Prevention Interventions in Lower- and Middle-Income Countries. <i>Annual Review of Public Health</i> , 2013, 34, 317-335.	7.6	52
12	Global Cardiovascular Therapy. , 2013, , 75-82.		0
13	A comparative evaluation of the quality of ten generic telmisartan tablets with the brand. <i>African Journal of Pharmacy and Pharmacology</i> , 2013, 7, 2043-2053.	0.2	0
14	Editorial (Heart Failure: The Need for Global Health Perspective). <i>Current Cardiology Reviews</i> , 2013, 9, 97-98.	0.6	10
15	Availability, prices and affordability of essential medicines in Haiti. <i>Journal of Global Health</i> , 2013, 3, 020405.	1.2	24
16	The Market Dynamics of Generic Medicines in the Private Sector of 19 Low and Middle Income Countries between 2001 and 2011: A Descriptive Time Series Analysis. <i>PLoS ONE</i> , 2013, 8, e74399.	1.1	44
17	Essential Medicines Are More Available than Other Medicines around the Globe. <i>PLoS ONE</i> , 2014, 9, e87576.	1.1	85
18	Price, availability and affordability of medicines. <i>African Journal of Primary Health Care and Family Medicine</i> , 2014, 6, E1-6.	0.3	32

#	ARTICLE	IF	CITATIONS
19	The macroeconomic impact of non-communicable diseases in China and India: Estimates, projections, and comparisons. <i>Journal of the Economics of Ageing</i> , 2014, 4, 100-111.	0.6	42
20	Polypill Opens a Path for Improving Adherence—. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2083-2085.	1.2	2
21	A national survey on availability, price and affordability of selected essential medicines for non-communicable diseases in Sri Lanka. <i>BMC Public Health</i> , 2014, 14, 817.	1.2	30
22	The Impact Of Direct Price Control On Pharmaceutical Prices In Egypt. <i>Value in Health</i> , 2014, 17, A19-A20.	0.1	1
23	Screening for cardiovascular disease risk and subsequent management in low and middle income countries: challenges and opportunities. <i>Public Health Reviews</i> , 2015, 36, 13.	1.3	16
24	Medicines availability for non-communicable diseases: the case for standardized monitoring. <i>Globalization and Health</i> , 2015, 11, 18.	2.4	34
25	A public health approach to global management of hypertension. <i>Lancet, The</i> , 2015, 385, 825-827.	6.3	67
26	Outcomes and costs of implementing a community-based intervention for hypertension in an urban slum in Kenya. <i>Bulletin of the World Health Organization</i> , 2016, 94, 501-509.	1.5	23
27	Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. <i>Circulation</i> , 2016, 133, 2076-2085.	1.6	122
28	Prevalence and prevention of cardiovascular disease and diabetes mellitus. <i>Pharmacological Research</i> , 2016, 113, 600-609.	3.1	381
29	Assessment of the scope and practice of evaluation among medical donation programs. <i>Globalization and Health</i> , 2016, 12, 69.	2.4	7
30	Where to now in cardiovascular disease prevention. <i>Atherosclerosis</i> , 2016, 251, 483-489.	0.4	2
31	25 by 25: Achieving Global Reduction in Cardiovascular Mortality. <i>Current Cardiology Reports</i> , 2016, 18, 10.	1.3	37
32	Extensions of indication throughout the drug product lifecycle: a quantitative analysis. <i>Drug Discovery Today</i> , 2016, 21, 348-355.	3.2	21
33	Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. <i>Lancet, The</i> , 2016, 387, 61-69.	6.3	272
34	Prices and availability of locally produced and imported medicines in Ethiopia and Tanzania. <i>Journal of Pharmaceutical Policy and Practice</i> , 2017, 10, 7.	1.1	26
35	Availability, Price, and Affordability of Selected Essential Medicines for Chronic Diseases in 11 Countries of the Asia Pacific Region: A Secondary Analysis. <i>Asia-Pacific Journal of Public Health</i> , 2017, 29, 268-277.	0.4	19
36	Developing Nephrology Programs in Low Resource Settings. , 2017, , 273-289.		1

#	ARTICLE	IF	CITATIONS
37	Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. <i>Lancet Public Health</i> , The, 2017, 2, e411-e419.	4.7	134
38	Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff. <i>BMC Health Services Research</i> , 2017, 17, 27.	0.9	17
39	Ensuring Patient-Centered Access to Cardiovascular Disease Medicines in Low-Income and Middle-Income Countries Through Health-System Strengthening. <i>Cardiology Clinics</i> , 2017, 35, 125-134.	0.9	19
40	Availability and affordability of antimalarial and antibiotic medicines in Malawi. <i>PLoS ONE</i> , 2017, 12, e0175399.	1.1	28
41	Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study. <i>International Journal for Equity in Health</i> , 2017, 16, 154.	1.5	24
42	Limited access to CVD medicines in low-income and middle-income countries: poverty is at the heart of the matter. <i>The Lancet Global Health</i> , 2018, 6, e234-e235.	2.9	11
43	Comparison of prescribing patterns between United States and Dominican Republic prescribers on short-term medical mission trips. <i>International Health</i> , 2018, 10, 27-32.	0.8	6
44	Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. <i>International Journal of Cardiology</i> , 2018, 262, 71-78.	0.8	18
45	Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990–2015: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 137-149.	1.0	63
46	A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery. <i>JAMA Ophthalmology</i> , 2018, 136, 1271.	1.4	22
47	Evaluating the accessibility of essential medicines in China. <i>Journal of Medical Economics</i> , 2018, 21, 784-792.	1.0	4
48	Availability, affordability and costs of pediatric medicines in Mongolia. <i>BMC Pediatrics</i> , 2018, 18, 149.	0.7	13
49	Quantifying the financial burden of households' out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data, 1994–2014. <i>BMJ Open</i> , 2018, 8, e018020.	0.8	109
50	Problems and Obstacles of Poorest Countries in Having Good Governance and Quality and Effective Pharmaceutical Policy. , 2018, , 387-401.		0
51	Public procurement of medicines: scoping review of the scientific literature in South America. <i>Journal of Pharmaceutical Policy and Practice</i> , 2019, 12, 33.	1.1	7
52	Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India. <i>BMJ Global Health</i> , 2019, 4, e001379.	2.0	35
53	The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study. <i>PLoS ONE</i> , 2019, 14, e0212125.	1.1	51
54	Medicine Prices in Africa. , 2019, , 85-111.		0

#	ARTICLE	IF	CITATIONS
55	Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon. BMC Health Services Research, 2019, 19, 973.	0.9	6
56	On affordability of statins therapy - comparative analysis between Ukraine and Bulgaria. BMC Health Services Research, 2019, 19, 902.	0.9	2
57	Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia. PLoS ONE, 2019, 14, e0226169.	1.1	22
58	The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries. Frontiers in Pharmacology, 2019, 10, 1375.	1.6	37
59	Price Studies for Specific Medicines. , 2019, , 113-164.		0
60	The Health Impact Fund: How Might It Work for Novel Anticoagulants in Atrial Fibrillation?. Global Heart, 2019, 9, 255.	0.9	2
61	Secondary CV Prevention in South America in a Community Setting: The PURE Study. Global Heart, 2017, 12, 305.	0.9	35
62	Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention and Control. Global Heart, 2018, 13, 143.	0.9	246
63	The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia's Social Health Insurance System. Value in Health Regional Issues, 2020, 21, 1-8.	0.5	17
64	Availability, prices and affordability of selected antibiotics and medicines against non-communicable diseases in western Cameroon and northeast DR Congo. PLoS ONE, 2020, 15, e0227515.	1.1	18
65	Interventions to increase the pharmacological adherence on arterial hypertension in Latin America: a systematic review. International Journal of Public Health, 2020, 65, 55-64.	1.0	5
66	Impact of pharmaceutical price controls on the cost of cardiovascular drugs: does essentiality matter?. Expert Review of Clinical Pharmacology, 2020, 13, 797-806.	1.3	2
67	Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Global Health, 2020, 5, e002640.	2.0	41
68	Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India. Tropical Medicine and International Health, 2020, 25, 1467-1479.	1.0	9
69	Availability, price, and affordability of WHO priority maternal and child health medicine in public health facilities of Dessie, north-East Ethiopia. BMC Medical Informatics and Decision Making, 2020, 20, 221.	1.5	12
70	Availability of equipment and medications for non-communicable diseases and injuries at public first-referral level hospitals: a cross-sectional analysis of service provision assessments in eight low-income countries. BMJ Open, 2020, 10, e038842.	0.8	15
71	Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. Journal of the American Heart Association, 2020, 9, e015302.	1.6	61
72	Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico. BMC Health Services Research, 2020, 20, 424.	0.9	13

#	ARTICLE	IF	CITATIONS
73	Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines. International Journal of Environmental Research and Public Health, 2020, 17, 1710.	1.2	6
74	Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study. PLoS ONE, 2020, 15, e0229307.	1.1	13
75	Access to Essential Cardiovascular Medicines in Pakistan: A National Survey on the Availability, Price, and Affordability, Using WHO/HAI Methodology. Frontiers in Pharmacology, 2020, 11, 595008.	1.6	8
76	Anti-hypertensive medication access and affordability and their association with blood pressure control at a teaching hospital in Ghana. Pan African Medical Journal, 2021, 39, 184.	0.3	6
77	Out of pocket payment, affordability and availability of essential medicines in Africa: systematic review. Journal of Analytical & Pharmaceutical Research, 2021, 10, 58-63.	0.3	1
78	Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal. Global Heart, 2021, 16, 38.	0.9	6
79	Priority Setting as an Ethical Imperative in Managing Global Dialysis Access and Improving Kidney Care. Seminars in Nephrology, 2021, 41, 230-241.	0.6	8
80	Impact of medication therapy management service on selected clinical and humanistic outcomes in the ambulatory diabetes patients of Tikur Anbessa Specialist Hospital, Addis Ababa, Ethiopia. PLoS ONE, 2021, 16, e0251709.	1.1	6
81	Availability of essential medicines in Pakistanâ€”A comprehensive document analysis. PLoS ONE, 2021, 16, e0253880.	1.1	5
82	Evaluation of availability, price, and affordability of cardiovascular, diabetes, and global medicines in Abuja, Nigeria. PLoS ONE, 2021, 16, e0255567.	1.1	6
83	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, The, 2021, 398, 957-980.	6.3	1,289
84	Integrating HIV and hypertension management in low-resource settings: Lessons from Malawi. PLoS Medicine, 2018, 15, e1002523.	3.9	44
85	Pharmaceutical Availability across Levels of Care: Evidence from Facility Surveys in Ghana, Kenya, and Uganda. PLoS ONE, 2014, 9, e114762.	1.1	26
86	Baseline assessment of WHOâ€™s target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS ONE, 2017, 12, e0171284.	1.1	105
87	Costs and Cost-Effectiveness of Interventions and Policies to Prevent and Treat Cardiovascular and Respiratory Diseases. , 2017, , 349-367.		7
88	Ischemic Heart Disease: Cost-Effective Acute Management and Secondary Prevention. , 2017, , 135-155.		8
89	Measuring Availability, Prices and Affordability of Ischaemic Heart Disease Medicines in Bangi, Selangor, Malaysia. The Malaysian Journal of Medical Sciences, 2019, 26, 113-121.	0.3	10
90	Change in affordability of medications in Kazan in 2011 and 2015 as a reflection of state initiatives to regulate drug prices. Kazan Medical Journal, 2017, 98, 822-826.	0.1	3

#	ARTICLE	IF	CITATIONS
91	The Role of Medicine Pricing Policy for Improving the Affordability of Medicines. Jurnal Ilmu Kefarmasian Indonesia, 2018, 16, 172.	0.0	0
92	Availability of Essential Medicines in a Country in Conflict: A Quantitative Insight from Yemen. International Journal of Environmental Research and Public Health, 2021, 18, 175.	1.2	7
93	Time to effectively address hypertension in India. Indian Journal of Medical Research, 2013, 137, 627-31.	0.4	19
94	The Availability and Affordability of Cardiovascular Medicines for Secondary Prevention in Tehran Province (Iran). Iranian Journal of Pharmaceutical Research, 2018, 17, 64-72.	0.3	9
95	Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria. Iranian Journal of Pharmaceutical Research, 2021, 20, 403-416.	0.3	0
96	The Economic Impact of Non-Communicable Disease in China and India: Estimates, Projections, and Comparisons. SSRN Electronic Journal, 0, , .	0.4	0
97	PASCAR and WHF Cardiovascular Diseases Scorecard project. Cardiovascular Journal of Africa, 2020, 31, 47-53.	0.2	4
98	Availability and Affordability of Medicines for Diabetes and Cardiovascular Disease across Countries: Information Learned from the Prospective Urban Rural Epidemiological Study. International Journal of Diabetology, 2022, 3, 236-245.	0.9	1
99	Prices, Availability And Affordability Of Essential Medicines For Non-Communicable Diseases: A Facility Based Survey In District Abbotabad. Pakistan Biomedical Journal, 2021, 4, .	0.0	1
100	Addressing Failures in Achieving Hypertension Control in Low- and Middle-Income Settings through Simplified Treatment Algorithms. Global Heart, 2022, 17, 28.	0.9	8
104	Comparative health systems analysis of differences in the catastrophic health expenditure associated with non-communicable vs communicable diseases among adults in six countries. Health Policy and Planning, 2022, 37, 1107-1115.	1.0	9
105	The economic burden of treating uncomplicated hypertension in Sub-Saharan Africa: a systematic literature review. BMC Public Health, 2022, 22, .	1.2	7
106	Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review. Public Health Reviews, 0, 43, .	1.3	4
107	Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. Journal of Human Hypertension, 2023, 37, 828-834.	1.0	7
108	Availability and affordability of cardiovascular medicines in a major city of Afghanistan in 2020. DARU, Journal of Pharmaceutical Sciences, 0, , .	0.9	0
109	Closing gaps in medication taking for secondary prevention of coronary heart disease patients among US adults. Heliyon, 2022, 8, e11530.	1.4	1
110	Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru. Journal of Pharmaceutical Policy and Practice, 2022, 15, .	1.1	1
111	The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: The case of Bangladesh. PLOS Global Public Health, 2022, 2, e0001154.	0.5	0

#	ARTICLE	IF	CITATIONS
112	The role of the private sector in noncommunicable disease prevention and management in low- and middle-income countries: a series of systematic reviews and thematic syntheses. International Journal of Qualitative Studies on Health and Well-being, 2023, 18, .	0.6	2
113	Changes in the burden and underlying causes of heart failure in the Eastern Mediterranean Region, 1990â€“2019: an analysis of the Global Burden of Disease Study 2019. EClinicalMedicine, 2023, 56, 101788.	3.2	5
114	Blood pressureâ€”lowering medication prescribing, its adherence to guidelines and relationship with blood pressure control at a family medicine department. Health Science Reports, 2023, 6, .	0.6	1